Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial
暂无分享,去创建一个
J. Ajani | Y. Doki | L. Wyrwicz | T. Makino | M. B. Blum Murphy | H. Kawakami | M. Di Bartolomeo | E. Holtved | M. Braghiroli | Jianming Xu | Apurva Patel | F. El hajbi | A. Adenis | Yuko Kitagawa | K. Kato | Ian Chau | Satoru Motoyama | Takashi Ogata | Chih-Hung Hsu | Carlos Amaya-Chanaga | Nan Hu | Yasuhiro Matsumura